1873 — VIVA Biotech Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for VIVA Biotech Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	323	697	2,104	2,380	2,156
Cost of Revenue
Gross Profit	156	305	651	816	738
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3.73	443	1,711	2,664	2,209
Operating Profit	319	253	393	-285	-53.7
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	281	-356	348	-459	-56
Provision for Income Taxes
Net Income After Taxes	266	-379	301	-504	-99.8
Minority Interest
Net Income Before Extraordinary Items
Net Income	266	-387	288	-528	-116
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	266	-387	163	-528	-116
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.183	-0.243	0.081	-0.259	-0.057
Dividends per Share